Please login to the form below

Not currently logged in
Email:
Password:

New member for Baxterís board of directors

Baxter International has elected Dr Wayne T Hockmeyer to serve as a member of its board of directors from September 2007

Baxter International has elected Dr Wayne T Hockmeyer to serve as a member of its board of directors from September 2007.

Hockmeyer founded MedImmune and served as its CEO and chairman from 1988 to 2000. MedImmune develops therapies for infectious disease, inflammatory disease and cancer and was recently acquired by AstraZeneca.

"Wayne is an exciting addition to our board of directors and we welcome the strong executive, scientific and operational experience he brings," said Robert L. Parkinson, Jr., Baxter's chairman and chief executive officer. "His extensive scientific and R&D expertise will be invaluable in helping Baxter achieve its innovation and growth objectives."

Before Medimmune, Hockmeyer was vice-president of laboratory research and product development at Praxis Biologics and served as chief of the department of immunology at Walter Reed Army Institute of Research.

Hockmeyer is a member of the boards of directors of Middlebrook Pharmaceuticals, GenVec and Idenix Pharmaceuticals.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics